



Republic of the Philippines
Department of Health

CENTRAL OFFICE BIDS AND AWARDS COMMITTEE

COBAC RESOLUTION NO. 2018-155-A

06 September 2018

**RECOMMENDING APPROVAL OF THE AWARD OF CONTRACT
FOR THE PROCUREMENT OF ABACAVIR, 300MG - REBID
IB NO. 2018-149-A**

WHEREAS, Open Competitive Bidding for the Procurement of Abacavir, 300mg - Rebid was conducted in accordance with Republic Act (RA) 9184 and its 2016 Revised Implementing Rules and Regulations (IRR) through the General Appropriations Act of 2018 with a Total Approved Budget for the Contract (ABC) of One Million Six Hundred Seventy Eight Thousand Two Hundred Sixty Philippine Pesos and Six Centavos (PhP1,678,260.06):

Item No.	Particular	Quantity	Unit	Total ABC (PhP)
1	Abacavir, 300mg	1,998	Bottle of 60's	1,678,260.06

WHEREAS, COBAC Resolution No. 2018-155 "Declaration of Failure of Bidding for the Procurement of Abacavir, 300mg under IB No. 2018-149-A, was approved;

WHEREAS, on 18 April 2018, Mandatory Review and Pre-procurement Conference was conducted at 9:00 AM at COBAC Conference Room, Department of Health (DOH) to discuss the details of the procurement at hand;

WHEREAS, the Technical Working Group (TWG) was created through the issuance of Department Personnel Order (DPO) COBAC No. 2018-328 dated 20 April 2018;

WHEREAS, on 26 April 2018, the COBAC-A issued a memorandum to Disease Prevention and Control Bureau – HIV-AIDS Program (DPCB – HIV-AIDSP) relative to the issues and concerns raised during the cited activity;

WHEREAS, on 04 May 2018, a follow up memorandum was issued to DPCB – HIV-AIDSP;

WHEREAS, on 09 May 2018, the COBAC-A received the revised PR from DPCB – HIV-AIDSP;

WHEREAS, on 15 May 2018, the revised PR was presented to the COBAC-A and subsequently decided with proceed with the procurement process;

WHEREAS, on 29 May 2018, the Invitation to Bid (IB) was posted in the PhilGEPS website and in other conspicuous places within the premises of the DOH. The advertisement of IB in the newspaper of general nationwide circulation pursuant to Section 31.2.1(c) of the 2016 IRR of RA 9184 shall not be required for contracts to be bid with an ABC of PhP10M and below for the procurement of goods;

WHEREAS, on 05 June 2018, the Pre-bidding Conference took place as scheduled at 10:00 AM at the COBAC Conference Room, DOH. However, no prospective bidder attended the cited conference;

WHEREAS, a Bid Bulletin No. 1, dated 08 June 2018 was issued to announce the changes made in the posted Bidding Documents;

WHEREAS, on 20 June 2018, the Submission and Opening of Bids took place as scheduled at 9:00 A.M. at the COBAC Conference Room, DOH. RBC-MDCC procured the bidding documents and subsequently its submitted bid;

WHEREAS, the first envelope, containing the Eligibility and Technical Documents was opened and the presence, completeness and correctness of all the documents were verified by the COBAC-A in the presence of the bidder's representative. Upon examination, RBC-MDCC was declared "ELIGIBLE";

WHEREAS, the second envelope, containing the Financial Proposal was opened and the presence, completeness and correctness of the Financial Documents were verified by the COBAC-A. Upon examination, the lone "ELIGIBLE" bidder, was rated "PASSED" and its bid was read out publicly and posted in the Abstract of Bid, to wit:

Name of Company					RBC-MDCC
Bid Security					BSD
Amount					N/A
Validity					N/A
REMARKS					ELIGIBLE / PASSED
Item No.	Item Description	Qty.	Unit	TOTAL ABC	BID PRICE AS READ (PhP)
1	Abacavir, 300mg	1,998	Bottle of 60's	1,678,260.06	1,678,260.06

WHEREAS, RBC-MDCC was declared Single Bidder (SB), subject to further arithmetical review and corrections of the financial bid, if necessary;

WHEREAS, the bid for the item listed below was found to be substantially complying:

Item No. 1: 1,998 bottle of 60's of Abavacir, 300mg, 60 tablets per bottle

Bidder No.	Company Name	ABC (PhP)	Bid as Read Amount (PhP)	% Variance from ABC
1	RBC-MDCC	1,678,260.06	1,678,260.06	0%

WHEREAS, on 21 June 2018, the detailed evaluation of the submitted proposal on the legal, technical and financial aspects of the documents of the Single Calculated Bid (SCB) was undertaken by the designated TWG;

WHEREAS, on the same date, the legal and financial TWG members, upon evaluation found RBC-MDCC as "complying" as to legal and financial requirements and submitted their evaluation report;

WHEREAS, on 27 June 2018, the TWG, upon evaluation, found RBC-MDCC as "complying" as to technical and financial requirements and submitted their report;

WHEREAS, on 04 July 2018, the financial TWG member upon evaluation, found RBC-MDCC as "complying" as to financial requirements and submitted its report;

WHEREAS, on 17 July 2018, the consolidated TWG report was presented to the COBAC-A during its 27th Regular Meeting and upon further review and deliberation, the Committee concurred with the TWG and decided to proceed with post-qualification evaluation upon receipt of the additional documentary requirements;

WHEREAS, on 18 July 2018, a notification was issued to RBC-MDCC through facsimile and electronic mail requesting for the submission of the post-qualification requirements;

WHEREAS, on 23 July 2018, the post-qualification documents were submitted by RBC-MDCC which was considered within the prescribed timeline wherein if the deadline for an activity falls on a non-working day (i.e. Saturday and Sunday), then the submission will be the next working day pursuant to Section 38.2 of 2016 IRR of RA 9184, and was subsequently forwarded to the TWG for evaluation;

WHEREAS, on 24 July 2018, the TWG, upon evaluation of the legal TWG member found RBC-MDCC "complying" as to legal requirements. The TWG-Technical member noted that the submitted brochure was not readable, and submitted their report;

WHEREAS, on 31 July 2018, upon evaluation of the financial TWG member found RBC-MDCC "complying" as to financial requirements and submitted its report;

WHEREAS, on 14 August 2018, due to unavailability of quorum, the presentation of the TWG evaluation was re-scheduled on 20 August 2018 at 2:00 PM at the COBAC Conference Room, DOH;

WHEREAS, on 20 August 2018, the TWG report was presented to the COBAC-A during its 31st Regular Meeting and upon further review and deliberation, the Committee decided to request the bidder to submit a clear or readable copy of the brochure;

WHEREAS, on 23 August 2018, the COBAC-A issued a letter to RBC-MDCC requesting for a clear or readable copy of the brochure;

WHEREAS, on 28 August 2018, the COBAC-A received the response of RBC-MDCC and subsequently forwarded to the TWG, for further review and evaluation;

WHEREAS, on 30 August 2018, the TWG-Technical upon evaluation found RBC-MDCC “responsive” and submitted its evaluation report;

WHEREAS, on 04 September 2018, the TWG report was presented to the COBAC-A during its 34th Regular Meeting and upon further review and deliberation, the Committee concurred with the TWG and declared RBC-MDCC “post-qualified”;

WHEREAS, on 06 September 2018, the TWG submitted the Bid Evaluation and Post-qualification Evaluation Reports citing RBC-MDCC “complying” on the submitted documents;

WHEREAS, the COBAC-A reviewed and deliberated the TWG report, as well as the documents and response submitted by the SCB and the following are the salient points of discussion:

Item No.	Description	Name of Bidder	ABC (PhP)	Bid Price (PhP)	TWG		COBAC-A	
					Finding	Recommendation	Finding	Recommendation
1	Abacavir, 300mg	RBC-MDCC	1,678,260.06	1,678,260.06	The SCB passed the evaluation and found to have complied with the legal, technical and financial requirements.	Complying	<ul style="list-style-type: none"> • COBAC-A conforms to the recommendation of the TWG. • RBC-MDCC is determined to be responsive and recommended for the award of contract. 	Single Calculated and Responsive Bid (SCRB)

WHEREAS, at the time of signing of this Resolution, there is no pending incident, no pending Request for Reconsideration, no pending protest and the COBAC-A followed the requirements set forth in RA 9184;

NOW THEREFORE, on the basis of the above, the herein members of the COBAC-A **HEREBY RESOLVES** to recommend the award of contract to **RBC-MDC Corporation** with a Total Contract Price of **One Million Six Hundred Seventy Eight Thousand Two Hundred Sixty Philippine Pesos and Six Centavos (PhP1,678,260.06)** inclusive of taxes for the item listed below:

Item No.	Particular	Qty.	Unit	Total Bid Price (PhP)
1	Abacavir, 300mg	1,998	Bottle of 60's	1,678,260.06


SEP 18 2018

Signed this ____ day of ____ 2018 at the Department of Health, San Lazaro Compound, Sta. Cruz, Manila.


CENTRAL OFFICE BIDS AND AWARDS COMMITTEE (COBAC) – A


LEONITA P. GORGOLON, MHA, MCHM, CEO VI
Regular Member



FERCHITO L. AVELINO, MD, PHSAE
Regular Member


MAR WYNN C. BELLO, MD, MPA
Regular Member


KENNETH G. RONQUILLO, MD, MPH, CESO III
Vice-Chairperson


NESTOR F. SANTIAGO, JR., MD, MPH, MHSA, CESO III
Assistant Secretary of Health
Chairperson

By Authority of the Secretary of Health:


RUBY C. CONSTANTINO, MD, MPH, CESO IV
OIC Director IV
Disease Prevention and Control Bureau

SEP 28 2018